iqvia report anoth solid quarter like narrow-
moat busi share remain overvalu
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim dec
price data feb
rate updat feb
currenc amount express
methodolog valu compani
anticip materi chang fair valu
estim narrow-moat iqvia report fourth-
quarter earn revenu earn came slightli
analyst expect fourth-quart
revenu nearli billion repres year-over-
year growth constant currenc top-lin growth
driven solid result technolog analyt nearli
constant currenc slightli expect
research develop constant
currenc line expect contract
sale segment continu declin expect
manag guidanc slightli lower
expect top line still comfort
long-term forecast mid- high-single-digit revenu
technolog analyt solut post
billion revenu fourth quarter driven demand
constantli chang portfolio commerci offer
includ oce platform
relationship manag market well double-
digit growth real-world evid offer manag
note compani work number
single-arm trial hybrid tradit clinic
trial use real-world data compar arm iqvia
abil leverag unmatch data asset drug
develop one pillar support compani narrow
moat expect iqvia maintain lead posit
emerg space real-world evid
research develop solut contribut
billion fourth-quart revenu pleas
see strong book growth last year
bring total backlog billion includ zero-
margin reimburs expens growth rate
book acceler throughout year
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
iqvia result merger quintil lead global contract
research organ im health lead healthcar data
analyt provid cro segment focus primarili provid
outsourc late-stag clinic trial pharmaceut devic
technolog servic client healthcar industri includ
pharmaceut compani provid payer policymak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
attribut robust oper environ
strong biotech fund continu biopharma drug
innov well compani sale effort
merger manag note rfp volum
increas expect momentum
continu
interestingli manag said expect
contract sale segment return growth fiscal
issu guidanc nearli flat full-year revenu
segment howev contract sale repres less
revenu believ busi
add much iqvia competit advantag
entir clear drive expect improv
segment expect like combin
favor oper environ better leverag
segment may adjust forecast segment
clariti manag
materi impact valuat
state earlier plan make
chang long-term outlook iqvia expect
expect revenu growth increment margin
improv fiscal like mark
continu invest oce relat technolog
offer real-world evid sale effort
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
